Evidence map›Paper›PMID 23695233›Full record

SynthesisTranslational psychiatry2013

Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy.

M J Bakermans-Kranenburg, M H van I Jzendoorn

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Translational psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06248710 (Effects of Intranasal Oxytocin on Trust Towards Therapists and Dogs), which is not on this map. Cited by 173 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 6 pooled it
59.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06248710 phase2 / phase3recruitingnot on this mapstarted 2024, after this paper: background citation

Effects of Intranasal Oxytocin on Trust Towards Therapists and Dogs: A Randomized Controlled Trial in Healthy Adults

TypeinterventionalSponsorDr. Karin HedigerRan2024 to 2024Enrolled176ConditionsDepressive Symptoms, Human-Animal InteractionArmsOxytocin nasal spray, Animal-Assisted Intervention, Placebo
3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 6 syntheses or guidelines pooled it, 385 citations in OpenAlex.

  1. Pooled it
  2. Social Support and Antibody Responses to Vaccination: A Meta-Analysis.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2020
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Oxytocin Amplifies Negative Response to Ambiguity in Adolescent Females With and Without Eating Disorders.European eating disorders review : the journal of the Eating Disorders Association · 2025
    Trial
  9. Trial
  10. Trial
  11. Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder.Autism research : official journal of the International Society for Autism Research · 2023
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Oxytocin and vasopressin modulation of prisoner's dilemma strategies.Journal of psychopharmacology (Oxford, England) · 2020
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Placebo treatment facilitates social trust and approach behavior.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Trial
  20. Trial

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

M J Bakermans-KranenburgCentre for Child and Family Studies, Rommert Casimir Institute for Developmental Psychopathology, Leiden University, Leiden, The Netherlands. bakermans@fsw.leidenuniv.nl
M H van I Jzendoorn
Leiden University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The popularity of oxytocin (OT) has grown exponentially during the past decade, and so has the number of OT trials in healthy and clinical groups. We take stock of the evidence from these studies to explore potentials and limitations of pharmacotherapeutic applications. In healthy participants, intranasally administered OT leads to better emotion recognition and more trust in conspecifics, but the effects appear to be moderated by context (perceived threat of the 'out-group'), personality and childhood experiences. In individuals with untoward childhood experiences, positive behavioral or neurobiological effects seem lowered or absent. In 19 clinical trials, covering autism, social anxiety, postnatal depression, obsessive-compulsive problems, schizophrenia, borderline personality disorder and post-traumatic stress, the effects of OT administration were tested, with doses ranging from 15 IU to more than 7000 IU. The combined effect size was d=0.32 (N=304; 95% confidence interval (CI): 0.18-0.47; P<0.01). However, of all disorders, only studies on autism spectrum disorder showed a significant combined effect size (d=0.57; N=68; 95% CI: 0.15-0.99; P<0.01). We hypothesize that for some of the other disorders, etiological factors rooted in negative childhood experiences may also have a role in the diminished effectiveness of treatment with OT.

Indexed as

Administration, IntranasalAnti-Anxiety AgentsAnxietyChildChild Development Disorders, PervasiveDepressionHumansMental DisordersOxytocinPersonality DisordersPhobic DisordersSchizophreniaStress Disorders, Post-TraumaticTrustAnti-Anxiety AgentsOxytocin

Identifiers

PMID23695233
PMCPMC3669921
OpenAlexW1966317054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.